morphosys
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA International
German biopharmaceutical company MorphoSys AG recommended on Thursday that an offer by Swiss pharmaceutical firm Novartis be accepted. MorphoSys' management board and supervisory board recommended that shareholders tender their MorphoSys shares. Novartis has offered MorphoSys shareholders €68 ($72.90) per share in cash, representing a total equity value of €2.7 billion. MorphoSys and Novartis maintain their expectation that the closing of the takeover offer will take place in the first half of 2024. The takeover offer requires a minimum acceptance threshold of 65% of MorphoSys' share capital. ...
DPA Breaking News
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA International
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA
German antitrust regulators have approved the takeover of German biotech company Morphosys by the Swiss pharmaceutical firm Novartis. Germany's Federal Cartel Office announced its approval of the transaction on Tuesday. Morphosys, which is headquartered near Munich, manufactures drugs to treat the blood cancers leukaemia. Andreas Mundt, who heads the regulatory agency, said officials had examined very carefully whether the merger would affect competition in the research and development of new drugs to treat leukaemia. Mundt said the agency's review found "no serious competition concerns." Many...
DPA Breaking News
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら